Catalent’s Chair & Chief Executive Officer, John Chiminski, Receives First Ever ‘Lifetime Achievement’ Award at CPhI Worldwide

Share Article

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that its Chair and Chief Executive Officer, John Chiminski, has received the inaugural CPhI Pharma Awards ‘Lifetime Achievement Award’ at the world’s largest pharmaceutical exhibition, CPhI Worldwide, currently taking place at Messe Frankfurt, Germany.

Catalent’s Chair & Chief Executive Officer, John Chiminski

Catalent’s Chair & Chief Executive Officer, John Chiminski

I am extremely proud to lead a company of highly talented people who are totally committed to bringing better, innovative treatments to market, in the shortest possible timeframe, ultimately improving patient outcomes.

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that its Chair and Chief Executive Officer, John Chiminski, has received the inaugural CPhI Pharma Awards ‘Lifetime Achievement Award’ at the world’s largest pharmaceutical exhibition, CPhI Worldwide, currently taking place at Messe Frankfurt, Germany.

The judges considered Mr. Chiminski to be ‘an exceptional individual with a consistent history of service, above and beyond the call of duty’ throughout his career. The award was announced at a Gala Dinner on Tuesday, November 5th. Established in 2004, the CPhI Pharma Awards are among the most prestigious recognitions within the pharmaceutical industry. The awards celebrate thinkers and creators breaking new ground and strongly advocate companies committed to driving the industry forward.

On receiving the award, Mr. Chiminski commented, “I would like to sincerely thank the judges and my industry peers for this recognition and feel deeply honored.” He added, “I am extremely proud to lead a company of highly talented people who are totally committed to bringing better, innovative treatments to market, in the shortest possible timeframe, ultimately improving patient outcomes.”

Over a 10-year period, Mr. Chiminski has led Catalent’s transformation into the world’s leading drug delivery technology, development and supply organization, overseeing a successful IPO in 2014. Since then he has driven the company’s growth strategy, both organically and through acquisitions, to ensure maximum return on investment for shareholders.

Today, he heads an organization employing nearly 13,000 people, including approximately 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue.

Mr. Chiminski joined Catalent after more than 20 years of experience at GE Healthcare in engineering, operations, and senior leadership roles.

He holds a Bachelors of Sciences from Michigan State University and a Master of Sciences from Purdue University, both in electrical engineering, as well as a master’s degree in management from the Kellogg School of Management at Northwestern University.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling
Catalent
+44 7580 041073
Email >

Richard Kerns
Visit website